ArticleBMC infectious diseases2025
Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- AI-assisted MALDI-TOF MS for identifying carbapenem resistance in clinicalEmerging microbes & infections · 2026Article
- Using the Damage Response Framework as a Lens to Discuss Acinetobacter baumannii Host-Pathogen Interactions: A Narrative Review and a Call to Action.Infectious diseases and therapy · 2026Review
- ESKAPE Pathogens in a Hungarian Emergency Department: A 5-Year Retrospective Observational Study of Prevalence and Resistance Patterns Utilizing the AWaRe Framework.Antibiotics (Basel, Switzerland) · 2026Article
- Exploratory Evaluation of Susceptibility Patterns of Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2026Article
- Repurposing bleomycin against Acinetobacter baumannii HisG: computational, biophysical, and antibacterial evidence.Journal of computer-aided molecular design · 2026Article
- Clinical Severity and Organ Dysfunction as Drivers of Mortality in Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Six Years ofAntibiotics (Basel, Switzerland) · 2026Article
- Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement.Infectious diseases and therapy · 2026Article
- Quercetin as a promising HIS-C inhibitor and novel therapeutic against antibacterial drug-resistant Acinetobacter baumannii: in vitro and in silico insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Carbapenem-resistantFrontiers in medicine · 2026Article
- Molecular Epidemiological Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Southern Lebanon.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidemiological data for United States (US) hospitals regarding the burden of Acinetobacter baumannii and carbapenem-resistant A. baumannii (CRAB) are scarce; thus, this study aimed to describe the incidence of A. baumannii and CRAB across US hospitals between January 1, 2018 and December 31, 2022.
methodsThis was a retrospective cohort study of hospitalized patients with microbiology data from the PINC AI™ Database. Incidence rates of A. baumannii and CRAB (January 1, 2018 - December 31, 2022) were determined across US hospitals in each census region. Incidence rates of A. baumannii and CRAB were determined at the hospitalization encounter and individual levels. Presence of CRAB was based on non-susceptibility to either doripenem, imipenem, or meropenem. Patient demographics, comorbidities, outcomes, including in-hospital mortality, were compared between patients with CRAB and carbapenem-susceptible A. baumannii (CSAB) at the hospitalization encounter level.
resultsDuring the study period, 7,270 hospitalization encounters with ≥ 1 A. baumannii clinical cultures were identified. The overall A. baumannii incidence rate was 1.19 cases per 100 hospitalization encounters and 1.33 cases per 100 unique patients. For CRAB, a total of 2,708 hospitalization encounters were identified, and incidence rate was 0.44 cases per 100 hospitalization encounters. The West South Central, East North Central, and East South Central regions had the highest CRAB incidence rates (0.78, 0.67, and 0.63 cases per 100 hospitalization encounters, respectively). Compared with CSAB, patients with CRAB had significantly more positive cultures with A. baumannii (20.9% vs. 10.0%, respectively, P < 0.0001) and higher prevalence of other Gram-negative pathogens in any clinical culture site within ± 3 days of the index A. baumannii clinical culture (47.2% vs. 42.9%, respectively, P = 0.0004). Patients with CRAB had higher incidences of in-hospital mortality vs. patients with CSAB (20.5% vs. 11.3%, respectively, P < 0.0001).
conclusionsPresence of A. baumannii was identified on a clinical culture in 1% of adult hospitalizations in this multicenter US study. Over a third of A. baumannii hospitalization encounters were CRAB, with the highest incidence rates per 100 hospitalization encounters observed in the most central US regions. Clinicians should consider A. baumannii as a potential pathogen in patients in regions with an increasing incidence rate of A. baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.